Enveric Biosciences Inc (NASDAQ: ENVB) will soon have a patent in hand for its EVM301 non-psychoactive, psychedelic-inspired drugs. The United States Patent and Trademark Office just gave Enveric a notice…
Read More
For years, the psychedelic renaissance focused on one clear idea. If you could deliver a guided psychedelic experience safely and predictably, you could lift people out of stubborn depression, trauma,…
Read More
The current state of the mental health system is a conversation that echoes in the halls of policy-making, the corners of social advocacy, and within the private struggles of individuals…
Read More
Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and…
Read More
Enveric Biosciences recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric's issued…
Read More
Microcap Enveric Biosciences (NASDAQ:ENVB) is threatening to take legal action against AbbVie (NYSE:ABBV) as it believes that the latter's major depressive disorder candidate bretisilocin, which it said it would acquire…
Read More
In the rush to stake a claim in next-generation mental health treatments, biotech headlines are dominated by billion-dollar acquisitions and bold clinical projections. But in the fine print—in courtrooms, patent…
Read More
Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed…
Read More
When AbbVie wrote a $1.2 billion cheque for Gilgamesh Pharmaceuticals’ Bretisilocin, it wasn’t just buying a drug, it was buying a future. That future, once dismissed as fringe science, is now being…
Read More
There’s a first time for everything, and now is the time for Enveric Biosciences to submit its first-ever IND to the FDA. After forgoing a Phase 1 in Australia and…
Read More
